Inhibition of thombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood form healthy male subjects

Thrombosis and Haemostasis

Volumn 87, Issue 2, 2002, Pages 300-305

  Sarich, Troy C ^a   Eriksson, Ulf G ^a   Mattsson, Christer ^a   Wolzt, Michael ^a   Frison, Lars ^a   Fager, Gunnar ^a   Gustafsson, David ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Melagatran; Oral direct thrombin inhibitor; Shed blood; Thrombin generation; Ximelagatran

Indexed keywords

BIOLOGICAL MARKER; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PROTHROMBIN; PROTHROMBIN FRAGMENT 1 PLUS 2; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE; PROTHROMBIN FRAGMENT 1.2;

ADULT; ARTICLE; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; FEEDBACK SYSTEM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ANTITHROMBIN III; AZETIDINES; BENZYLAMINES; DALTEPARIN; FEEDBACK; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; THROMBIN;

EID: 0036007936     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612989     Document Type: Article

References (23)

1. Pathobiology of thrombin in acute coronary syndromes
2. Thrombin and antithrombotics
3. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
4. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation
5. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo: Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (Fragmin)
6. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man - Effect of low dose aspirin
7. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds
8. Localization of the tissue factor in the normal vessel wall and in the atherosclerotic plaque
9. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
10. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
11. Tissue factor in atherosclerosis
12. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen
13. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
14. Single and repeated oral dosing of H 376/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects
15. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects
16. Low molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease
17. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man
18. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment
19. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
20. The effect of melagatran on the binding of thrombin to antithrombin studied by plasmon resonance
21. The mechanisms of action of alpha- and beta-isoforms of antithrombin
22. Inhibition of protein C activation by anticoagulant compounds with different modes of action
23. Methro II: Dose-response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement